GHRS earnings date and last-quarter result: last quarter miss, P/E -31.07. Updated 2026-07-23.
GH Research (GHRS) Research Hub
GH Research (GHRS) trades on NASDAQ, IE in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 19.18 USD (+6.14%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -31.07, market cap 1.95B. This hub links to the full technical, earnings and options research available for GHRS.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, IE |
| Last close | 19.18 USD (+6.14%) |
| 52-week range | 17.54 USD – 31.44 USD |
| Trend regime | Range |
| 14-day RSI | 36.1 (Bearish) |
| Trailing P/E | -31.07 |
| Market cap | 1.95B |
| Dividend yield | 0.00% |
Available research for GHRS
Covered Call on GHRS: how it works, illustrative setup around the real 19.18 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on GHRS: how it works, illustrative setup around the real 19.18 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on GHRS: how it works, illustrative setup around the real 19.18 USD price, max profit/loss, breakeven and when to use it. Educational.
GHRS technical analysis: range, last 19.18 USD, RSI 36.1, 52w range 17.54 USD–31.44 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is GHRS in?
GH Research (GHRS) is classified under Healthcare (Biotechnology), listed on NASDAQ, IE.
Is GHRS in an uptrend or downtrend?
As of 2026-10-26, GHRS is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is GHRS's trailing P/E ratio?
GHRS's trailing P/E is -31.07, with a market cap of 1.95B. See the earnings research page for full valuation detail.